Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD

American Journal of Kidney Diseases

Volumn 63, Issue 6, 2014, Pages 869-887

  Ruzicka, Marcel ^a   Quinn, Robert R ^b,c   McFarlane, Phil ^d   Hemmelgarn, Brenda ^b,c   Ramesh Prasad, G V ^d   Feber, Janusz ^e   Nesrallah, Gihad ^f,g   Mackinnon, Martin ^h   Tangri, Navdeep ⁱ   McCormick, Brendan ^a   Tobe, Sheldon ^j   Blydt Hansen, Tom D ⁱ   Hiremath, Swapnil ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^h SAINT JOHN REGIONAL HOSPITAL   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Canadian Society of Nephrology (CSN); chronic kidney disease (CKD); clinical practice guideline; commentary; Hypertension; Kidney Disease: Improving Global Outcomes (KDIGO)

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADVERSE OUTCOME; ALBUMINURIA; BLOOD PRESSURE REGULATION; CANADA; CEREBROVASCULAR ACCIDENT; CHILD CARE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CREATININE CLEARANCE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EXERCISE; GERIATRIC PATIENT; GRAFT RECIPIENT; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; ORTHOSTATIC HYPOTENSION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REVIEW; SALT INTAKE; SYSTOLIC BLOOD PRESSURE; WEIGHT CONTROL;

CANADIAN SOCIETY OF NEPHROLOGY (CSN); CHRONIC KIDNEY DISEASE (CKD); CLINICAL PRACTICE GUIDELINE; COMMENTARY; HYPERTENSION; KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO);

CANADA; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; SOCIETIES, MEDICAL; SODIUM, DIETARY;

EID: 84901490967     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.03.003     Document Type: Article

References (70)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 1 2012 337 414
2. G.H. Guyatt, A.D. Oxman, H.J. Schunemann, P. Tugwell, and A. Knottnerus GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology J Clin Epidemiol 64 4 2011 380 382
3. D.G. Hackam, R.R. Quinn, and P. Ravani et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension Can J Cardiol 29 5 2013 528 542
4. A. Levin, B. Hemmelgarn, and B. Culleton et al. Guidelines for the management of chronic kidney disease CMAJ 179 11 2008 1154 1162
5. R.E. Gilbert, D. Rabi, and P. LaRochelle et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Treatment of Hypertension Can J Diabetes 37 suppl 1 2013 S117 S118
6. M.C. Brouwers, M.E. Kho, and G.P. Browman et al. The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines J Clin Epidemiol 65 5 2012 526 534
7. K.M. Rose, M.L. Eigenbrodt, and R.L. Biga et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study Circulation 114 7 2006 630 636
8. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy Neurology 46 5 1996 1470
9. F.H. Leenen, N.H. McInnis, and G. Fodor Obesity and the prevalence and management of hypertension in Ontario, Canada Am J Hypertens 23 9 2010 1000 1006
10. K.C. Abbott, C.W. Glanton, and F.C. Trespalacios et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study Kidney Int 65 2 2004 597 605
11. S. Zhu, Z. Wang, S. Heshka, M. Heo, M.S. Faith, and S.B. Heymsfield Waist circumference and obesity-associated risk factors among whites in the Third National Health and Nutrition Examination Survey: clinical action thresholds Am J Clin Nutr 76 4 2002 743 749
12. E.F. Elsayed, H. Tighiouart, and D.E. Weiner et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD Am J Kidney Dis 52 1 2008 49 57
13. F. Razak, S.S. Anand, and H. Shannon et al. Defining obesity cut points in a multiethnic population Circulation 115 16 2007 2111 2118
14. M. Chiu, P.C. Austin, D.G. Manuel, B.R. Shah, and J.V. Tu Deriving ethnic-specific BMI cutoff points for assessing diabetes risk Diabetes Care 34 8 2011 1741 1748
15. N.J. Aburto, A. Ziolkovska, L. Hooper, P. Elliott, F.P. Cappuccio, and J.J. Meerpohl Effect of lower sodium intake on health: systematic review and meta-analyses BMJ 346 2013 f1326
16. T.M. Vogt, L.J. Appel, and E. Obarzanek et al. Dietary Approaches to Stop Hypertension: rationale, design, and methods. DASH Collaborative Research Group J Am Diet Assoc 99 suppl 8 1999 S12 S18
17. M. Burnier, J. Biollaz, J.L. Magnin, M. Bidlingmeyer, and H.R. Brunner Renal sodium handling in patients with untreated hypertension and white coat hypertension Hypertension 23 4 1994 496 502
18. E.J. McMahon, J.D. Bauer, and C.M. Hawley et al. A randomized trial of dietary sodium restriction in CKD J Am Soc Nephrol 24 12 2013 2096 2103
19. I. de Brito-Ashurst, L. Perry, and T.A. Sanders et al. The role of salt intake and salt sensitivity in the management of hypertension in South Asian people with chronic kidney disease: a randomised controlled trial Heart 99 17 2013 1256 1260
20. H.L. Walls, A. Peeters, J. Proietto, and J.J. McNeil Public health campaigns and obesity - a critique BMC Public Health 11 2011 136
21. B.K. Nallamothu, R.A. Hayward, and E.R. Bates Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies Circulation 118 12 2008 1294 1303
22. H.O. Dickinson, J.M. Mason, and D.J. Nicolson et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials J Hypertens 24 2 2006 215 233
23. S. Heiwe, and S.H. Jacobson Exercise training for adults with chronic kidney disease Cochrane Database Syst Rev 10 2011 CD003236
24. E. Nuesch, S. Trelle, and S. Reichenbach et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study BMJ 341 2010 c3515
25. E. Wuhl, A. Trivelli, and S. Picca et al. Strict blood-pressure control and progression of renal failure in children N Engl J Med 361 17 2009 1639 1650
26. J.T. Wright Jr., G. Bakris, and T. Greene et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431
27. P. Ruggenenti, A. Perna, and G. Loriga et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial Lancet 365 9463 2005 939 946
28. S. Klahr, A.S. Levey, and G.J. Beck et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 13 1994 877 884
29. J.C. Peterson, S. Adler, and J.M. Burkart et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 10 1995 754 762
30. L.J. Appel, J.T. Wright Jr., and T. Greene et al. Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 10 2010 918 929
31. P.M. Rothwell Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 9454 2005 176 186
32. E.M. Davis, L.J. Appel, and X. Wang et al. Limitations of analyses based on achieved blood pressure: lessons from the African American Study of Kidney Disease and Hypertension trial Hypertension 57 6 2011 1061 1068
33. A. Upadhyay, A. Earley, S.M. Haynes, and K. Uhlig Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Ann Intern Med 154 8 2011 541 548
34. J.F. Mann, H.C. Gerstein, and Q.L. Yi et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study J Am Soc Nephrol 14 3 2003 641 647
35. T. Saruta, K. Hayashi, T. Ogihara, K. Nakao, T. Fukui, and K. Fukiyama Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study Hypertens Res 32 6 2009 505 512
36. J.F. Mann, R.E. Schmieder, and L. Dyal et al. Effect of telmisartan on renal outcomes: a randomized trial Ann Intern Med 151 1 2009 1 10 W11-W12
37. H. Makino, M. Haneda, and T. Babazono et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes Diabetes Care 30 6 2007 1577 1578
38. H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 2001 870 878
39. T.H. Jafar, P.C. Stark, and C.H. Schmid et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 4 2003 244 252
40. D.M. Kent, T.H. Jafar, and R.A. Hayward et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease J Am Soc Nephrol 18 6 2007 1959 1965
41. J.F. Mann, R.E. Schmieder, and M. McQueen et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 9638 2008 547 553
42. S. Yusuf, K. Teo, and C. Anderson et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 9644 2008 1174 1183
43. S. Bangalore, S. Kumar, I. Lobach, and F.H. Messerli Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials Circulation 123 24 2011 2799 2810 2799, p following 2810
44. J.L. Abramson, C.T. Jurkovitz, V. Vaccarino, W.S. Weintraub, and W. McClellan Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study Kidney Int 64 2 2003 610 615
45. V. Perkovic, T. Ninomiya, and H. Arima et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 18 10 2007 2766 2772
46. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch, and S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 8 2001 629 636
47. A.K. Bello, B. Hemmelgarn, and A. Lloyd et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes Clin J Am Soc Nephrol 6 6 2011 1418 1426
48. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 7160 1998 703 713
49. R.W. Schrier, R.O. Estacio, A. Esler, and P. Mehler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 3 2002 1086 1097
50. R.W. Schrier, R.O. Estacio, P.S. Mehler, and W.R. Hiatt Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 3 8 2007 428 438
51. G. Reboldi, G. Gentile, F. Angeli, G. Ambrosio, G. Mancia, and P. Verdecchia Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients J Hypertens 29 7 2011 1253 1269
52. W.C. Cushman, G.W. Evans, and R.P. Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 17 2010 1575 1585
53. M. Rahman, S. Pressel, and B.R. Davis et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 8 2005 936 946
54. C.Y. Hsu, C.E. McCulloch, J. Darbinian, A.S. Go, and C. Iribarren Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease Arch Intern Med 165 8 2005 923 928
55. L. Hansson, A. Zanchetti, and S.G. Carruthers et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 9118 1998 1755 1762
56. G. Opelz, and B. Dohler Improved long-term outcomes after renal transplantation associated with blood pressure control Am J Transplant 5 11 2005 2725 2731
57. B.L. Kasiske, M.G. Zeier, and J.R. Chapman et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary Kidney Int 77 4 2010 299 311
58. G.A. Knoll, M. Cantarovitch, and E. Cole et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation - study design Nephrol Dial Transplant 23 1 2008 354 358
59. T. Seeman, M. Pohl, J. Misselwitz, and U. John Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors Kidney Blood Press Res 32 6 2009 440 444
60. M. Mitsnefes, P.L. Ho, and P.T. McEnery Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) J Am Soc Nephrol 14 10 2003 2618 2622
61. J.T. Flynn, M. Mitsnefes, and C. Pierce et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study Hypertension 52 4 2008 631 637
62. S. Furth, J.T. Flynn, C. Pierce, and M. Mitsnefes Lower systolic BP associated with slower CKD progression in the CKiD study [abstract] J Am Soc Nephrol 21 2013 551A
63. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents Pediatrics 114 2 suppl 4th Report 2004 555 576
64. J.T. Flynn, C.B. Pierce, and E.R. Miller III et al. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease J Pediatr 160 3 2012 434 440 e431
65. R.G. VanDeVoorde, and M.M. Mitsnefes Hypertension and CKD Adv Chronic Kidney Dis 18 5 2011 355 361
66. J. Samuels, D. Ng, and J.T. Flynn et al. Ambulatory blood pressure patterns in children with chronic kidney disease Hypertension 60 1 2012 43 50
67. F. Angeli, G. Reboldi, and P. Verdecchia Masked hypertension: evaluation, prognosis, and treatment Am J Hypertens 23 9 2010 941 948
68. T. Seeman, D. Palyzova, J. Dusek, and J. Janda Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension J Pediatr 147 3 2005 366 371
69. M. Litwin, A. Niemirska, M. Ruzicka, and J. Feber White coat hypertension in children: not rare and not benign? J Am Soc Hypertens 3 6 2009 416 423
70. T. Sulakova, and J. Feber Should mean arterial pressure be included in the definition of ambulatory hypertension in children? Pediatr Nephrol 28 7 2013 1105 1112